Business News • PR NewsWire • New Efficacy Data Shows Cimzia(R) (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn's Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW

New Efficacy Data Shows Cimzia(R) (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn's Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW

New Efficacy Data Shows Cimzia(R) (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn's Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW

ATLANTA, May 2 /PRNewswire/ -- UCB announced today results of an open-label extension study, PRECiSE 4 (P4), of Cimzia® (certolizumab pegol; CZP) demonstrating that Cimzia provides sustained efficacy over four years in moderate to severe Crohn's Disease patients regardless of whether patients w

View More : http://www.prnewswire.com/news-releases/new-efficacy-data-shows-cimziar-certolizumab-pegol-provides-long-term-remission-...

Releted News by prnewswire

First Lady Michelle Obama's Sutra Jewels Cuff

New Studies Examine Adverse Outcomes Associated With Obesity and More Applicable Measures of Obesity

Children's Safety, Health May Be Jeopardized by Misinformation

New Efficacy Data Shows Cimzia(R) (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn's Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW

Rentrak Announces Box Office Numbers for Weekend of April 30, 2010

Media, Politicos & Hollywood Stars Shake Up Washington at Niche Media's Capitol File Magazine's Fifth Annual White House Correspondents' Association Dinner After Party, Presented by Bing and Renaissance Hotels